Home > Neurology > Valproate tied to highest risk of T2DM in adults versus other anticonvulsant mood stabilizers

Valproate tied to highest risk of T2DM in adults versus other anticonvulsant mood stabilizers


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Journal
JAMA Network Open
Reuters Health -  14/04/2022 - Among anticonvulsant mood stabilizers, valproate is associated with the highest risk of developing type 2 diabetes mellitus (T2DM) in adults, whereas lamotrigine conferred the lowest risk, a cohort study suggests.  Anticonvulsant mood stabilizers are widely used by adults and children for the treatment of epilepsy, bipolar disorder, and neuropathic pain.  "The most surprising takeaway is that metabolic risk could be an important consideration to weigh when starting treatment," Dr. Jenny Sun of Harvard Medical School and Harvard Pilgrim Health Care Institute in Boston told Reuters Health by email. "Metabolic risk is often a less kn...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on